Patents by Inventor Suzie Chen

Suzie Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11229704
    Abstract: Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: January 25, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Atif J. Khan, Suzie Chen, James S. Goydos, Bruce G. Haffty
  • Publication number: 20210138067
    Abstract: Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.
    Type: Application
    Filed: November 20, 2020
    Publication date: May 13, 2021
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Atif J. Khan, Suzie Chen, James S. Goydos, Bruce G. Haffty
  • Publication number: 20210078962
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 18, 2021
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Patent number: 10864271
    Abstract: Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: December 15, 2020
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Atif Jalees Khan, Suzie Chen, James S. Goydos, Bruce G. Haffty
  • Patent number: 10844026
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: November 24, 2020
    Assignees: Biohaven Pharmaceutical Holding Company Ltd., Rutgers, The State University of New Jersey
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Publication number: 20200157069
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 21, 2020
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Patent number: 10562870
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: February 18, 2020
    Assignee: Biohaven Pharmaceutical Holding Company Ltd.
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark Mcdonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Publication number: 20170334870
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: August 4, 2017
    Publication date: November 23, 2017
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark Mcdonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Patent number: 9725427
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 8, 2017
    Assignees: Biohaven Pharmaceutical Holding Company Limited, Rutgers, The State University of New Jersey
    Inventors: Garry R. Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery C. Pelletier, Venkata N. Velvadapu, Jay E. Wrobel
  • Publication number: 20150045401
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew Douglas Vera, Benjamin Eric Blass, Jeffrey Claude Pelletier, Venkata Naga Velvadapu, Jay Edward Wrobel
  • Patent number: 8835473
    Abstract: The present invention provides methods of treating cancer using 2-amino-6-trifluoromethoxybenzothiazole (riluzole). In one aspect, the present invention provides methods of reducing cancer cell growth. In another aspect, the present invention provides a method of inducing apoptosis in a cancer cell. In another aspect, the present invention provides a method of reducing the growth of a glutamate-releasing tumor.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: September 16, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: James S. Goydos, Suzie Chen
  • Publication number: 20100221246
    Abstract: The present invention provides methods of treating cancer using 2-amino-6-trifluoromethoxybenzothiazole (riluzole). In one aspect, the present invention provides methods of reducing cancer cell growth. In another aspect, the present invention provides a method of inducing apoptosis in a cancer cell. In another aspect, the present invention provides a method of reducing the growth of a glutamate-releasing tumor.
    Type: Application
    Filed: September 15, 2009
    Publication date: September 2, 2010
    Applicants: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: James S. Goydos, Suzie Chen
  • Patent number: 7691377
    Abstract: A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM1 antagonist, or a combination thereof
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: April 6, 2010
    Assignee: Rutgers, The State University of New Jersey
    Inventors: James S. Goydos, Suzie Chen
  • Publication number: 20080263685
    Abstract: The present invention provides transgenic non-human animal models and cell lines which express a metabotropic glutamate receptor 1 in a melanocyte-specific manner and, as a result, exhibit a predisposition to the development of melanoma. The invention further teaches methods of using the transgenic animals and cell lines to identify therapeutic agents. Diagnostic methods for detecting a melanoma are also provided.
    Type: Application
    Filed: April 28, 2008
    Publication date: October 23, 2008
    Inventor: Suzie Chen
  • Patent number: 7385103
    Abstract: The present invention provides transgenic non-human animal models and cell lines which express a metabotropic glutamate receptor 1 in a melanocyte-specific manner and, as a result, exhibit a predisposition to the development of melanoma. The invention further teaches methods of using the transgenic animals and cell lines to identify therapeutic agents. Diagnostic methods for detecting a melanoma are also provided.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: June 10, 2008
    Assignee: Rutgers, the State University
    Inventor: Suzie Chen
  • Publication number: 20080124333
    Abstract: A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM 1 antagonist, or a combination thereof
    Type: Application
    Filed: September 14, 2007
    Publication date: May 29, 2008
    Applicants: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: James S. Goydos, Suzie Chen
  • Publication number: 20050235366
    Abstract: The present invention provides transgenic non-human animal models and cell lines which express a metabotropic glutamate receptor 1 in a melanocyte-specific manner and, as a result, exhibit a predisposition to the development of melanoma. The invention further teaches methods of using the transgenic animals and cell lines to identify therapeutic agents. Diagnostic methods for detecting a melanoma are also provided.
    Type: Application
    Filed: March 28, 2005
    Publication date: October 20, 2005
    Inventor: Suzie Chen